<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE OF REVIEW: As <z:e sem="disease" ids="C0206247" disease_type="Disease or Syndrome" abbrv="">amyloid neuropathies</z:e> have benefited from recent major progress, this review is timely and relevant </plain></SENT>
<SENT sid="1" pm="."><plain>RECENT FINDINGS: The main recent articles on <z:e sem="disease" ids="C0206247" disease_type="Disease or Syndrome" abbrv="">amyloid neuropathy</z:e> cover its description, methods for diagnosis and therapies </plain></SENT>
<SENT sid="2" pm="."><plain>Varied clinical presentations are described in transthyretin (TTR)-familial <z:hpo ids='HP_0011034'>amyloidosis</z:hpo> with <z:hpo ids='HP_0001271'>polyneuropathy</z:hpo> (FAP) and light chain <z:e sem="disease" ids="C0206247" disease_type="Disease or Syndrome" abbrv="">amyloid neuropathy</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Mass spectrometry is able to identify the biochemical nature of amyloidogenic protein in nerve biopsy and skin biopsy samples for diagnosis of small fiber <z:hpo ids='HP_0001271'>polyneuropathy</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Both nerve biopsy and TTR gene sequencing are important to identify <z:hpo ids='HP_0003745'>sporadic</z:hpo> cases of <z:e sem="disease" ids="C0206247" disease_type="Disease or Syndrome" abbrv="">amyloid neuropathy</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>Nerve biopsy is useful in demonstrating the amyloid origin of <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathies</z:e> developing after domino liver transplant recipients </plain></SENT>
<SENT sid="6" pm="."><plain>Liver transplantation improves long-term survival in Met30 TTR-FAP </plain></SENT>
<SENT sid="7" pm="."><plain>Factors recognized as leading to <z:hpo ids='HP_0001638'>cardiomyopathy</z:hpo> progression or heart involvement after liver transplantation are late disease <z:hpo ids='HP_0003674'>onset</z:hpo> and fibril composition </plain></SENT>
<SENT sid="8" pm="."><plain>Combined heart and liver transplantation is recommended in severe <z:hpo ids='HP_0001723'>restrictive cardiomyopathy</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>Antiamyloid drugs are emerging: tafamidis, a TTR stabilizer, showed in a phase III controlled study its ability to slow stage 1 FAP progression </plain></SENT>
<SENT sid="10" pm="."><plain>Other strategies are emerging for TTR-FAP (combination <z:chebi fb="1" ids="50845">doxycycline</z:chebi>-tauroursodeoxycholic acid, small interfering <z:chebi fb="40" ids="33697">RNA</z:chebi>, antisense oligonucleotide, monoclonal antibody antiserum amyloid P component) </plain></SENT>
<SENT sid="11" pm="."><plain>For light chain <z:e sem="disease" ids="C0442874" disease_type="Disease or Syndrome" abbrv="">neuropathy</z:e>, intensive chemotherapy may be helpful </plain></SENT>
<SENT sid="12" pm="."><plain>SUMMARY: There is better recognition of <z:e sem="disease" ids="C0206247" disease_type="Disease or Syndrome" abbrv="">amyloid neuropathies</z:e>, and hope for enrolling patients with FAP in future clinical trials testing new antiamyloid drugs </plain></SENT>
</text></document>